MX2022005522A - Formas de sal de un receptor de componente c5a de complemento. - Google Patents

Formas de sal de un receptor de componente c5a de complemento.

Info

Publication number
MX2022005522A
MX2022005522A MX2022005522A MX2022005522A MX2022005522A MX 2022005522 A MX2022005522 A MX 2022005522A MX 2022005522 A MX2022005522 A MX 2022005522A MX 2022005522 A MX2022005522 A MX 2022005522A MX 2022005522 A MX2022005522 A MX 2022005522A
Authority
MX
Mexico
Prior art keywords
salt forms
receptor
complement component
compound
complement
Prior art date
Application number
MX2022005522A
Other languages
English (en)
Inventor
Ju Yang
Howard S Roth
Yibin Zeng
Penglie Zhang
Rajinder Singh
Rebecca M Lui
Kwok Yau
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MX2022005522A publication Critical patent/MX2022005522A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se proporcionan formas de sal de un receptor del componente del complemento 5a que tiene la fórmula del compuesto 1 (ver Fórmula) (compuesto 1). En la presente también se proporcionan composiciones farmacéuticas y métodos de tratamiento que utilizan las formas de sal del compuesto 1, descrito en la presente.
MX2022005522A 2019-11-08 2020-11-06 Formas de sal de un receptor de componente c5a de complemento. MX2022005522A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962932658P 2019-11-08 2019-11-08
PCT/US2020/059291 WO2021092295A1 (en) 2019-11-08 2020-11-06 Salt forms of a complement component c5a receptor

Publications (1)

Publication Number Publication Date
MX2022005522A true MX2022005522A (es) 2022-06-08

Family

ID=75846470

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005522A MX2022005522A (es) 2019-11-08 2020-11-06 Formas de sal de un receptor de componente c5a de complemento.

Country Status (14)

Country Link
US (1) US11427541B2 (es)
EP (1) EP4054541A4 (es)
JP (1) JP2022553835A (es)
KR (1) KR20220099989A (es)
CN (1) CN114867473A (es)
AU (1) AU2020380367A1 (es)
BR (1) BR112022008183A2 (es)
CA (6) CA3235574A1 (es)
CL (1) CL2022001183A1 (es)
IL (1) IL292371A (es)
MX (1) MX2022005522A (es)
TW (1) TW202128623A (es)
WO (1) WO2021092295A1 (es)
ZA (1) ZA202204442B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022007489A2 (pt) 2019-11-08 2022-07-12 Chemocentryx Inc Forma amorfa de um receptor c5a de componente do complemento
JP2022554019A (ja) * 2019-11-08 2022-12-27 ケモセントリックス，インコーポレイティド 補体成分Ｃ５ａ受容体の遊離塩基結晶形態
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289879B1 (en) 2004-09-27 2014-11-12 Acadia Pharmaceuticals Inc. Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt
EP3078658B1 (en) 2008-12-22 2019-04-10 ChemoCentryx, Inc. C5ar antagonists
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
PL2585064T3 (pl) 2010-06-24 2017-09-29 Chemocentryx, Inc. Antagoniści C5AR
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
CN111670185A (zh) 2017-10-31 2020-09-15 凯莫森特里克斯股份有限公司 减少尿sCD163的C5aR抑制剂
BR112020024842A2 (pt) 2018-06-07 2021-03-02 Chemocentryx, Inc. dosagem e efeito de antagonista de c5a com vasculite associada a anca
MX2021011008A (es) * 2019-03-11 2021-10-13 Inflarx Gmbh Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.
BR112022007489A2 (pt) 2019-11-08 2022-07-12 Chemocentryx Inc Forma amorfa de um receptor c5a de componente do complemento
JP2022554019A (ja) 2019-11-08 2022-12-27 ケモセントリックス，インコーポレイティド 補体成分Ｃ５ａ受容体の遊離塩基結晶形態

Also Published As

Publication number Publication date
US20210139427A1 (en) 2021-05-13
CA3236258A1 (en) 2021-05-14
BR112022008183A2 (pt) 2022-07-12
WO2021092295A1 (en) 2021-05-14
TW202128623A (zh) 2021-08-01
EP4054541A4 (en) 2023-12-20
CL2022001183A1 (es) 2023-02-17
AU2020380367A1 (en) 2022-05-12
JP2022553835A (ja) 2022-12-26
CN114867473A (zh) 2022-08-05
US11427541B2 (en) 2022-08-30
CA3235574A1 (en) 2021-05-14
IL292371A (en) 2022-06-01
CA3236256A1 (en) 2021-05-14
CA3155950A1 (en) 2021-05-14
KR20220099989A (ko) 2022-07-14
ZA202204442B (en) 2023-09-27
EP4054541A1 (en) 2022-09-14
CA3236253A1 (en) 2021-05-14
CA3236249A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
ZA202204442B (en) Salt forms of a complement component c5a receptor
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
CR20220251A (es) Nuevos derivados de metilquinazolinona
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
MX2020009857A (es) Conjugados de interleucina-2 (il-2).
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
ZA202305624B (en) Amorphous form of a complement component c5a receptor
ZA202305622B (en) Free base crystalline form of a complement component c5a receptor
PH12019501955A1 (en) Tri-cycle compound and applications thereof
PH12019550154A1 (en) Azetidine derivative
MX2021012105A (es) Compuestos de pirrol.
MX2021007247A (es) Derivados de rapamicina.
WO2018039077A8 (en) Therapeutic compounds
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
MX2021009717A (es) Sulfonamidas biciclicas.
MX2021003232A (es) Inhibidores de o-glicoproteina-2-acetamido-2-desoxi-3-d-glucopiran osidasa.
WO2018102256A8 (en) Pyrrolidinone compounds
PH12021550323A1 (en) Dendrimer formulations
MX2021014458A (es) Compuestos triciclicos.
MY198328A (en) Adamantylmethylamine Derivative and use Thereof as Pharmaceutical
SA522431572B1 (ar) مركب بيريميدين-5-كربوكساميد
MX2022006984A (es) Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina.